No Data
No Data
BriaCell Therapeutics: Promising Phase 3 Trial Progress and Strategic Financial Management Justify Buy Rating
Express News | HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $32 Price Target
BriaCell Therapeutics Analyst Ratings
BriaCell Says It Has Consented Over 100 And Has Enrolled Over 75 Patients In Phase 3 Study Of Bria-IMT Plus Immune Check Point Inhibitor Versus Physician's Choice In Advanced Metastatic Breast Cancer
Express News | Briacell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)